Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 8/20 | 0.39 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4511239 | 1.00 | ERBB2 (0.39) | ERBB2MINK1NPC1HPGDRAB9A | |
| SCHEMBL4515224 | 0.90 | ERBB2 (0.42) | ERBB2MINK1 | |
| SCHEMBL4515219 | 0.90 | ERBB2 (0.42) | ERBB2MINK1 | |
| SCHEMBL4508522 | 0.90 | ERBB2 (0.51) | ERBB2MINK1 | |
| SCHEMBL4508516 | 0.90 | ERBB2 (0.51) | ERBB2MINK1 | |
| SCHEMBL4513526 | 0.87 | ERBB2 (0.37) | ERBB2MINK1 | |
| SCHEMBL4513523 | 0.87 | ERBB2 (0.37) | ERBB2MINK1 | |
| SCHEMBL4510104 | 0.81 | ERBB2 (0.41) | ERBB2MINK1MAPT | |
| SCHEMBL4510107 | 0.81 | ERBB2 (0.41) | ERBB2MINK1MAPT | |
| SCHEMBL4514666 | 0.77 | ERBB2 (0.40) | ERBB2MINK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264485-A1 | Pyrazole Derivatives, Their Manufacture and Their Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | US | claimed |
| CN-101208335-A | Pyrazole derivatives, their manufacture and their use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | claimed |
| EP-1915370-A1 | PYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND THEIR USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-04-30 | — | — | EP | claimed |
| WO-2007017222-A1 | PYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND THEIR USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | claimed |
| US-20090264485-A1 | Pyrazole Derivatives, Their Manufacture and Their Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | US | disclosed |
| US-20090264485-A1 | Pyrazole Derivatives, Their Manufacture and Their Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | US | disclosed |
| US-20090264485-A1 | Pyrazole Derivatives, Their Manufacture and Their Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | US | disclosed |
| CN-101208335-A | Pyrazole derivatives, their manufacture and their use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | disclosed |
| EP-1915370-A1 | PYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND THEIR USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007017222-A1 | PYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND THEIR USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017222-A1 | PYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND THEIR USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264485-A1 | Pyrazole Derivatives, Their Manufacture and Their Use as Pharmaceutical Agents | CYP3A5, CYP3A43, CYP3A7 | ERBB2 3732/4885MINK1 1721/4885NPC1 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.